ClinCalc Pro
Menu
Calculators Drugs Pathways AI Dx Donate Get the App
Erythropoietin Stimulating Agent (Anaemia of Prematurity) Pregnancy: Neonatal use only — not applicable to pregnant women.

Erythropoietin (Epoetin Alfa/Beta — Anaemia of Prematurity)

Brand names: Eprex (epoetin alfa), NeoRecormon (epoetin beta)

Adult dose

Dose: Not applicable for prematurity — adult CKD anaemia doses in renal.json
Route: N/A
Frequency: N/A
Max: N/A
Adult anaemia of CKD — see renal specialty file.

Paediatric dose

Dose: Anaemia of prematurity: 200 units/kg three times weekly (epoetin alfa or beta). Range 200–250 units/kg three times weekly SC units/kg
Route: Subcutaneous injection
Frequency: Three times weekly
Max: 250 units/kg per dose (750 units/kg/week)
Anaemia of prematurity in neonates <34 weeks GA who require blood transfusion reduction strategy. Start at 5–14 days of life when haemodynamically stable. Duration: 4–6 weeks or until haemoglobin ≥12 g/dL. Must be supplemented with iron (elemental iron 3–6 mg/kg/day orally or 2–3 mg/kg/day IV) — without adequate iron, EPO is ineffective. Source: BNF for Children 2024; BAPM Guidelines.

Dose adjustments

Renal

No dose adjustment in prematurity context — dose is empirical weight-based.

Hepatic

No dose adjustment required.

Paediatric weight-based calculator

Anaemia of prematurity in neonates <34 weeks GA who require blood transfusion reduction strategy. Start at 5–14 days of life when haemodynamically stable. Duration: 4–6 weeks or until haemoglobin ≥12 g/dL. Must be supplemented with iron (elemental iron 3–6 mg/kg/day orally or 2–3 mg/kg/day IV) — without adequate iron, EPO is ineffective. Source: BNF for Children 2024; BAPM Guidelines.

Clinical pearls

  • Anaemia of prematurity mechanism: extremely premature neonates have shortened red cell lifespan, inadequate erythropoietin production relative to anaemia severity (EPO is normally produced in the liver in neonates, not kidney — less adaptive response), and frequent phlebotomy for blood tests. EPO stimulates bone marrow erythropoiesis but requires adequate iron stores.
  • Transfusion threshold debate: erythropoietin was introduced to reduce blood transfusion exposure in premature infants (exposure to donor blood risks immunological sensitisation, transfusion reactions, and infection). However, meta-analyses show modest benefit — EPO reduces number of transfusions by approximately 0.7 per infant. Major trials (PINT, ELBW studies) suggest it may not reduce total red cell volume transfused significantly.
  • ROP warning — MHRA: a signal for increased retinopathy of prematurity (ROP) rate was identified with high-dose EPO in some trials. MHRA recommends: only use EPO in extremely premature infants with access to regular ophthalmological screening for ROP. The biological mechanism: EPO stimulates retinal neovascularisation via VEGF pathways — similar to the mechanism of ROP itself.
  • Iron supplementation is mandatory: start iron supplementation (elemental iron 3–6 mg/kg/day) within 1 week of starting EPO. Without iron, erythropoiesis cannot proceed even with adequate EPO stimulation — iron-deficiency anaemia develops rapidly. Monitor serum ferritin (target >100 micrograms/L during EPO therapy).
  • Neonatal EPO vs darbepoetin: darbepoetin alfa (longer half-life, once-weekly dosing) has been used off-label in neonatal units as an alternative to epoetin three times weekly. Evidence base is similar to epoetin. Both require iron co-supplementation. Source: BNF for Children 2024; Aher et al. Cochrane 2020 (early EPO anaemia of prematurity); MHRA ROP warning.

Contraindications

  • Uncontrolled hypertension
  • Haemoglobin ≥12 g/dL (overshooting target — thrombosis risk)
  • Pure red cell aplasia (PRCA) — previous EPO-related PRCA

Side effects

  • Injection site reactions (SC — most common; rotate sites)
  • Hypertension (EPO-induced erythrocytosis increases blood viscosity — monitor BP)
  • Thrombosis (polycythaemia risk — avoid target Hb >12 g/dL in neonates)
  • Retinopathy of prematurity (ROP) — controversial evidence; some studies show increased risk with high-dose EPO; MHRA warning; only use with ophthalmological surveillance
  • Seizures (rare — associated with rapid rise in haematocrit)

Interactions

  • Iron supplements: required concomitantly — EPO without iron replacement is ineffective (iron is rate-limiting for erythropoiesis)
  • Thrombosis risk: EPO increases platelet activation — monitor with antiplatelet drugs

Monitoring

  • Haemoglobin (aim to maintain 8–11 g/dL in premature neonates — avoid >12 g/dL to reduce thrombosis risk)
  • Serum ferritin (target >100 micrograms/L — ensure adequate iron available for erythropoiesis)
  • Reticulocyte count (response marker — expected increase within 1–2 weeks)
  • Blood pressure (EPO-induced hypertension)
  • Ophthalmological review (ROP screening — especially with EPO use)

Reference: BNF for Children 2024; Aher et al. Cochrane 2020; BAPM Anaemia of Prematurity Guidelines; MHRA Safety Warning EPO ROP. Verify against your local formulary and the latest BNF before prescribing.

Related

Curated clinical cross-links plus same-class fallbacks.

Calculators
Pathways